Medindia

X

FDA Asks Sanofi to Assess Potential Neurocognitive Side Effects of Experimental Cholesterol Drug

by Kathy Jones on  March 8, 2014 at 10:26 PM Drug News   - G J E 4
Sanofi confirmed that it has been asked by the US Food and Drug Administration to assess the potential neurocognitive side effects of its experimental cholesterol drug which it has developed in partnership with Regeneron Pharmaceuticals.
 FDA Asks Sanofi to Assess Potential Neurocognitive Side Effects of Experimental Cholesterol Drug
FDA Asks Sanofi to Assess Potential Neurocognitive Side Effects of Experimental Cholesterol Drug
Advertisement

The drug, alirocumab, belongs to an experimental class known as PCSK9 inhibitors that reduce bad or LDL cholesterol by blocking the PCSK9 protein which is linked with maintaining high levels of the cholesterol in the blood stream.

Advertisement
However the FDA said it was "aware of concerns raised with neurocognitive adverse events" and has asked the two companies to assess the side effects.

Amgen Inc is also developing a similar drug, evolocumab, and the company revealed that it has also been contacted by the agency. "Similar to other companies developing PCSK9 inhibitors, Amgen has been in communication with the FDA, and we will continue to investigate the potential for cognitive impairment in our program", the company said in a statement.


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All